AstraZeneca plc has teamed up with
the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make
the first disclosed industry play for inhibitors of MALT1. The deal announcement caps five
years of progress toward validating MALT1 in B cell lymphoma and autoimmune
the last five years, a series of key studies-most of which were featured in SciBX-strengthened
the therapeutic rationale of targeting MALT1 in B cell lymphoma and broadened
the potential applications of inhibiting MALT1 to autoimmune disease.
Cain, C. SciBX 7(5);
Published online Feb. 6, 2014
1. Ruefli-Brasse, A.A. et
al. Science 302, 1581-1584 (2003)
2. Coornaert, B. Nat.
Immunol. 9, 263-271 (2008)
3. Rebeaud, F. Nat.
Immunol. 9, 272-281 (2008)
4. Hailfinger, S. et
al. Proc. Natl. Acad. Sci. USA 106, 19946-19951 (2009)
5. Ferch, U. et al. J.
Exp. Med. 206, 2313-2320 (2009)
6. Rosebeck, S. et al.
Science 331, 468-472 (2011)
7. Nagel, D. et al.
Cancer Cell 22, 825-837 (2012)
8. Fontan, L. et al.
Cancer Cell 22, 812-824 (2012)
9. Brüstle, A. et al.
J. Clin. Invest. 122, 4698-4709 (2012)
10. Mc Guire, C. et al.
J. Immunol. 190, 2896-2903 (2013)
11. Schlauderer, F. et
al. Angew. Chem. Int. Ed. 52, 10384-10387 (2013)
AND INSTITUTIONS MENTIONED
(LSE:AZN; NYSE:AZN), London, U.K.
The Campbell Family Institute for Breast Cancer Research at
The Princess Margaret,
Toronto, Ontario, Canada
Catholic University Leuven, Leuven, Belgium
Centre for Drug Design and Discovery, Leuven, Belgium
Flanders Institute for Biotechnology, Ghent, Belgium
South San Francisco, Calif.
German Research Center for Environmental Health, Munich, Germany
National Cancer Institute, Bethesda, Md.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Technical University Munich, Munich, Germany
University of Lausanne, Lausanne, Switzerland
University of Michigan, Ann Arbor, Mich.
University of Toronto, Toronto, Ontario, Canada
Weill Cornell Medical College, New York, N.Y.